Oncocyte Corp Files 10-Q for Q2 2024

TL;DR

Oncocyte Corp's Q2 2024 10-Q is in. Check financials.

AI Summary

Oncocyte Corp filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key financial data and business activities are presented for the reporting period.

Why It Matters

This 10-Q filing provides investors and stakeholders with the latest financial and operational status of Oncocyte Corp, crucial for understanding the company's performance and future outlook.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that could reveal positive or negative trends impacting the company's stock.

Key Numbers

• N/A — Revenue (Specific revenue figures for Q2 2024 are not detailed in this header information.)
• N/A — Net Income/Loss (Specific net income or loss figures for Q2 2024 are not detailed in this header information.)
• N/A — Cash Flow (Specific cash flow figures for Q2 2024 are not detailed in this header information.)

Key Players & Entities

• Oncocyte Corp (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240808 (date) — Filing date of the 10-Q
• 15 Cushing, Irvine, CA 92618 (location) — Business and mailing address

FAQ

Key Financial Figures

• $1 — , net of allowance for credit losses of $1 and $5, respectively 85 484 Prepaid
• $5 — f allowance for credit losses of $1 and $5, respectively 85 484 Prepaid expens

Filing Documents

• form10-q.htm (10-Q) — 2097KB
• ex10-7.htm (EX-10.7) — 176KB
• ex10-8.htm (EX-10.8) — 184KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 16KB
• ex32-1.htm (EX-32.1) — 9KB
• 0001493152-24-030793.txt ( ) — 10704KB
• ocx-20240630.xsd (EX-101.SCH) — 56KB
• ocx-20240630_cal.xml (EX-101.CAL) — 76KB
• ocx-20240630_def.xml (EX-101.DEF) — 333KB
• ocx-20240630_lab.xml (EX-101.LAB) — 497KB
• ocx-20240630_pre.xml (EX-101.PRE) — 438KB
• form10-q_htm.xml (XML) — 2081KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 43

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 55

Controls and Procedures

Item 4. Controls and Procedures 55

- OTHER INFORMATION

PART II - OTHER INFORMATION 56

Legal Proceedings

Item 1. Legal Proceedings 56

Risk Factors

Item 1A. Risk Factors 56

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57

Default Upon Senior Securities

Item 3. Default Upon Senior Securities 57

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 57

Other Information

Item 5. Other Information 57

Exhibits

Item 6. Exhibits 58

SIGNATURES

SIGNATURES 59 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would") should also be considered to be forward-looking statements. Forward-looking of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking those mentioned in this Report under Risk Factors and those Risk Factors in Part I, Item 1A of our most recent Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission ("SEC"). Except as required by law, Oncocyte undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. The

forward-looking statements include, among other things, statements about

forward-looking statements include, among other things, statements about: the timing and potential achievement of future milestones; the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers; our plans to pursue research and development of diagnostic test candidates; the potential commercialization of diagnostic tests currently in development; the timing and success of future clinical research and the period during which the results of the clinical research will become available; the potential receipt of revenue from current sales of our diagnostic tests and/or diagnostic tests in development; our assumptions regarding obtaining reimbursement and reimbursement rates of our current diagnostic tests and/or diagnostic tests in development; our estimates regarding future orders of tests and our ability to perform a projected number of tests; our estimates and assumptions around the patient populations, market size and price points for reimbursement for our diagnostic tests our estimates regarding future revenues, operating expenses, and future capital requirements; our intellectual property position; the impact of government laws and regulations; and our competitive position. Unless the context otherwise requires, all references to "Oncocyte," "we," "us," "our," "the Company" or similar words refer to Oncocyte Corporation, together with our consolidated subsidiaries. The description or discussion, in this Report, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement. DetermaIO, DetermaCNI, and VitaGraft are trademarks of Oncocyte, regardless of whether the "TM" symbol accompanies the use of or reference to the applicable trademark in this Report. 3 PART 1—FINANCIAL INFORMATION Item 1. Financial Statements. ONCOCYTE CORPORATION CONDENSE

View Full Filing

View this 10-Q filing on SEC EDGAR